Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: What bioanalysts should know about their reagents

Bioanalysis

Volumn 3, Issue 5, 2011, Pages 523-534

  Staack, Roland F ^a   Stracke, Jan O ^a   Stubenrauch, Kay ^a   Vogel, Rudolf ^a   Schleypen, Julia ^a   Papadimitriou, Apollon ^a  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; REAGENT;

ACCURACY; ANALYSIS; BINDING AFFINITY; BINDING ASSAY; BIOANALYSIS; CROSS REACTION; DRUG SCREENING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IMMUNOASSAY; INTERMETHOD COMPARISON; LIGAND BINDING; PURIFICATION; REPRODUCIBILITY; REVIEW; STORAGE TEMPERATURE;

ANIMALS; CHEMISTRY TECHNIQUES, ANALYTICAL; HUMANS; INDICATORS AND REAGENTS; PROTEINS; QUALITY CONTROL;

EID: 79953113665     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.11.16     Document Type: Review

References (24)

1. Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 134, 825-834 (2009).
2. Damen CW, Schellens JH, Beijnen JH. Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies. Hum. Antibodies 18(3), 47-73 (2009).
3. Geng D, Shankar G, Schantz A, Rajadhyaksha M, Davis H, Wagner C. Validation of immunoassays used to assess immunogenicity to therapeutic monoclonal antibodies. J. Pharm. Biomed. Anal. 39(3-4), 364-375 (2005). (Pubitemid 41196039)
4. Mire-Sluis AR, Barrett YC, Devanarayan V etal. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Methods 289(1-2), 1-16 (2004). (Pubitemid 38900899)
5. Wadhwa M, Thorpe R. Unwanted immunogenicity: Lessons learned and future challenges. Bioanalysis 2(6), 1073-1084 (2010).
6. Kuang B, King L, Wang HF. Therapeutic monoclonal antibody concentration monitoring: Free or total? Bioanalysis 2(6), 1125-1140 (2010). Very informative review on assay formats.
7. DeSilva B, Smith W, Weiner R etal. Recommendations for the bioanalytical method validation of ligand-bindingassays to support pharmacokinetic assessments of macromolecules. Pharm. Res. 20(11), 1885-1900 (2003). (Pubitemid 37449466)
8. Smolec J, DeSilva B, Smith W etal. Bioanalytical method validation for macromolecules in support of pharmacokinetic studies. Pharm. Res. 22(9), 1425-1431 (2005). (Pubitemid 41215881)
9. Findlay JW, Smith WC, Lee JW etal. Validation of immunoassays forbioanalysis: A pharmaceutical industry perspective. J. Pharm. Biomed. Anal. 21(6), 1249-1273 (2000). (Pubitemid 30001554)
10. Viswanathan CT, Bansal S, Booth B etal. Quantitative bioanalytical methods validation and implementation: Best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
11. Miller KJ, Bowsher RR, Celniker A etal. Workshop on bioanalytical methods validation for macromolecules: Summary report. Pharm. Res. 18(9), 1373-1383 (2001). (Pubitemid 32846335)
12. Shankar G, Devanarayan V, Amaravadi L etal. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48(5), 1267-1281 (2008).
13. Liang M, Klakamp SL, Funelas C etal. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5(5), 655-662 (2007).
14. Lofgren JA, Dhandapani S, Pennucci JJ etal. Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J. Immunol. 178(11), 7467-7472 (2007). (Pubitemid 46847475)
15. Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat. Biotechnol. 22(11), 1383-1391 (2004). (Pubitemid 39482857)
16. Kelley M, DeSilva B. Key elements of bioanalytical method validation for macromolecules. AAPSJ. 9(2), E156-E163 (2007). (Pubitemid 46812967)
17. Nowatzke W, Woolf E. Best practices during bioanalytical method validation for the characterization of assay reagents and the evaluation of analyte stability in assay standards, quality controls, and study samples. AAPSJ. 9(2), E117-E122 (2007). (Pubitemid 46690951)
18. Rup B, O'Hara D. Critical ligand binding reagent preparation/selection: When specificity depends on reagents. AAPSJ. 9(2), E148-E155 (2007). First paper dedicated to the importance of the quality of critical ligand-binding assay reagents. Covers different aspects and provides an excellent overview. (Pubitemid 46812920)
19. Gross J, Moller R, Henke W, Hoesel W. Detection of anti-EPO antibodies in human sera by a bridging ELISA is much more sensitive when coating biotinylated rhEPO to streptavidin rather than using direct coating of rhEPO. J. Immunol. Methods 313(1-2), 176-182 (2006).
20. European Medicines Agency (EMA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. EMEA/CHMP/BMWP/14327/2006 (2007).
21. Stubenrauch K, Wessels U, Vogel R, Schleypen J. Evaluation of a biosensor immunoassay for simultaneous characterization of isotype and binding region of human anti-tocilizumab antibodies with control by surrogate standards. Anal. Biochem. 390(2), 189-196 (2009).
22. Hoesel W, Gross J, Moller R etal. Development and evaluation of a new ELISA for the detection and quantification of antierythropoietin antibodies in human sera. J. Immunol. Methods 294(1-2), 101-110 (2004). (Pubitemid 39626595)
23. Organisation for Economic Co-operation and Development. OECD series on principles of good laboratory practice and comliance monitoring, Number 1 (as revised in 1997). ENV/MC/CHEM 98(17) (1998).
24. Pace CN, Vajdos F, Fee L, Grimsley G, GrayT. How to measure and predict the molar absorption coefficient of a protein. Protein Sci. 4(11), 2411-2423 (1995).